Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 29 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost of treatment of primary biliary cirrhosis with ursodeoxycholic acid

This month's Alimentary Pharmacology & Therapeutics investigates the cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid.

News image

Long-term use of ursodeoxycholic acid is the recommended therapy in primary biliary cirrhosis.

The lifetime effectiveness and cost-effectiveness of ursodeoxycholic acid in primary biliary cirrhosis have, however, not been assessed.

Dr Boberg and colleagues from Norway estimated the health outcomes and lifetime costs of a Norwegian cohort of primary biliary cirrhosis patients on ursodeoxycholic acid.

Norwegian primary biliary cirrhosis patients who were included in a 5-year open-label study of ursodeoxycholic acid therapy were subsequently followed up for up to 12 years.

The lifetime survival was estimated using a Weibull survival model.

There was a 82% probability that ursodeoxycholic acid entails greater life expectancy
Alimentary Pharmacology & Therapeutics

The survival benefit from ursodeoxycholic acid was based on a randomized clinical trial from Canada, comparing the effect of non-ursodeoxycholic acid and ursodeoxycholic acid.

Survival and costs of standard care vs. standard care plus ursodeoxycholic acid were simulated in a Markov model with death and liver transplantation as major events, invoking transition of a patient's state in the model.

The team analyzed the gain in life expectancy for a primary biliary cirrhosis patient on ursodeoxycholic acid compared with standard care was about 2 years.

The researchers found that lifetime treatment costs were EUR 151,403 and EUR 157,741 for patients with and without ursodeoxycholic acid, respectively.

A probabilistic sensitivity analysis indicated an 82% probability that ursodeoxycholic acid entails both greater life expectancy and lower costs than standard care.

Dr Boberg's team concludes, "The results of this study indicate that ursodeoxycholic acid therapy is a dominant strategy as it confers reduced morbidity and mortality, as well as cost savings, compared with standard therapy."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12435
21 August 2013

Go to top of page Email this page Email this page to a colleague

 29 August 2016 
Risk factor for post-ERCP pancreatitis
 29 August 2016 
Hep B immunization of infants for liver cancer
 29 August 2016 
Reducing Hep B-related HCC
 26 August 2016 
Celiac disease therapeutics
 26 August 2016 
Reasons for premature surveillance colonoscopy
 26 August 2016 
Bleeding after endoscopic dissection-induced gastric ulcers
 25 August 2016 
Short-chain fatty acids in mixed refractory constipation
 25 August 2016 
Stool DNA test for colorectal cancer screening
 25 August 2016 
Post-infectious IBS in C. diff
 24 August 2016 
Hep B after infant vaccination program
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 24 August 2016 
Genetics and therapy response in IBD
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us